Therapeutic advances in hormone-dependent cancers: focus on prostate, breast and ovarian cancers

Hormonal cancers affect over 400,000 men and women and contribute collectively to over 100,000 deaths in the United States alone. Thanks to advances in the understanding of these cancers at the molecular level and to the discovery of several disease-modifying therapeutics, the last decade has seen a...

Full description

Saved in:
Bibliographic Details
Published in:Endocrine Connections 2019-02, Vol.8 (2), p.R10-R26
Main Authors: Ulm, Michael, Ramesh, Arvind V, McNamara, Keely M, Ponnusamy, Suriyan, Sasano, Hironobu, Narayanan, Ramesh
Format: Article
Language:English
Subjects:
breast cancer
drug development
ovarian cancer
prostate cancer
Review
therapeutics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hormonal cancers affect over 400,000 men and women and contribute collectively to over 100,000 deaths in the United States alone. Thanks to advances in the understanding of these cancers at the molecular level and to the discovery of several disease-modifying therapeutics, the last decade has seen a plateauing or even a decreasing trend in the number of deaths from these cancers. These advanced therapeutics not only effectively slow the growth of hormonal cancers, but also provide an insight on how these cancers become refractory and evolve as an altogether distinct subset. This review summarizes the current therapeutic trends in hormonal cancers, with focus on prostate, breast and ovarian cancers. The review discusses the clinical drugs being used now, promising molecules that are going through various stages of development and makes some predictions on how the therapeutic landscape will shift in the next decade.
ISSN:2049-3614
2049-3614
DOI:10.1530/EC-18-0425